NORTH CHICAGO, Ill., Oct. 6, 2025 /PRNewswire/ -- AbbVie (ABBV) today announced positive topline results from the Phase 2 ELATE trial evaluating the safety and efficacy of onabotulinumtoxinA (BOTOX®) ...
NORTH CHICAGO, Ill., Oct. 6, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from the Phase 2 ELATE trial evaluating the safety and efficacy of onabotulinumtoxinA ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果